Open Targets Platform

Open Targets Platform 20.11 released!

We have a new release of the Open Targets Platform - 20.11 - which includes data updates from ClinVar (EVA), Genomics England, PhenoDigm, PheWAS Catalog, and CRISPR, along with the removal of more duplicated evidence, and a small change in our tractability buckets

experimental science

In-GenIE-ous experiments to find causal variants from GWAS

We developed a new method that can be used to screen up to a few dozen SNPs for a causal effect on gene transcription. We call it GenIE — Genome engineering-based Interrogation of Enhancers, and it was recently published in Nucleic Acids Research.

Open Targets Platform

How we improved our clinical trial curation during the COVID-19 lockdown

Learn how we leveraged the wide range of expertise amongst our lab-based experimental research colleagues to make valuable contributions to the Open Targets Platform and our target validation projects.

Open Targets Platform

The importance of Autophagy in drug discovery

Explore Reactome's new autophagy pathway and how it relates to drug discovery and the Open Targets Platform

Open Targets Platform

Introducing ClinGen’s Gene Validity Curations

Learn how the Open Targets Platform integrates and scores ClinGen's Gene-Disease Validity curation data to enhance rare disease associations

Open Targets Platform

Open Targets Platform 20.09 released!

We have a new release of the Open Targets Platform - 20.09 - which includes new data from ClinGen, updated Gene2Phenotype data, the removal of duplicated evidence, more clinical trial data, plus regular data updates

Genetics

Accessing Open Targets Genetics using GraphQL

A step-by-step guide to accessing the Open Targets Genetics portal using the GraphQL API.

coronavirus infectious disease

Open Targets releases our COVID-19 Target Prioritisation Tool

Open Targets is excited to introduce our COVID-19 Target Prioritisation Tool - http://covid19.opentargets.org/ - an interactive web portal allows users to explore host and viral targets and potential COVID-19 treatments

release notes

Open Targets Platform 20.06 has been released!

We have a new release of the Open Targets Platform with new disease terms including COVID-19, new chemical probes, updates to Open Targets Genetics evidence and more.

Open Targets Platform

Open Targets Platform: adding FDA data with Scala and Spark

Leveraging Spark and Scala to implement a performant ELT pipeline to integrate the FDA Adverse Event Reporting System into the Open Targets Platform

release notes

Open Targets Platform 20.04 has been released!

We have a new release of the Open Targets Platform with new target safety data, new target tractability modalities, more chemical probes and new associations.

Q&A

Prioritising your list of potential drug targets with tractability assessments

How tractable is a drug target? In this Open Targets Q&A, we explore the ChEMBL tractability (druggability) pipeline implemented in the Open Targets Platform.

Open Targets Genetics

GWAS causal inference in Open Targets

Finding GWAS causal inference for target identification and prioritisation using Open Targets Genetics and the Open Targets Platform.

Open Targets Platform

Open Targets in the time of Covid-19

In this blog, I explore the utility and limitations of COVID-19 data in the Open Targets Platform to find treatments for this new infectious disease.

Q&A

Special Q&A with Gosia Trynka, Open Targets Experimental Science director

We're delighted to have caught up with Gosia Trynka, our new Experimental Science director, for a very special Q&A on Open Targets science and more.

Genetics releases

Open Targets Genetics: new release is out

We're pleased to announce the latest release of Open Targets Genetics (March 2020) is out with a new locus-to-gene score to prioritise protein-coding genes at all published GWAS-associated loci.

release notes

Open Targets Platform: release 20.02 is out

We have a new release of the Open Targets Platform with a brand new data source, Open Targets Genetics Portal, more chemical probes and new intOGen data.

Cancer

An Open Targets Away Day with The Institute of Cancer Research

Open Targets meets colleagues at the Institute of Cancer Research in London: potential collaboration ahead of us.

Q&A

Getting to know intOGen, a resource for the identification of cancer driver genes

Open Targets Q&A on identifying cancer driver genes and their mechanism of action with intOGen.

ontology

EFO3: A community-driven ontology to advance clinical discoveries

In the 19.11 release of the Open Targets Platform, we moved from EFO2 to EFO3. Here we explore what the new disease ontology means to Open Targets.

Open Targets Platform

Using ChEMBL for target identification and prioritisation

Open Targets Q&A on the identification of cancer driver genes and their mechanism of action using intOGen. Using ChEMBL for target identification and prioritisation

release notes

Open Targets Platform: release 19.11 is out

We have a new release of the Open Targets Platform: new EFO3, FDA pharmacovigilance data, new chemical probes, more targets, more evidence and associations.

A-Z

From antibody to zinc finger: an A-Z of Open Targets

As scientists discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. November is time for H.

release notes

Open Targets Platform: release 19.09 is out

We have a new release of the Open Targets Platform: more target-disease associations, more chemical probes and target enabling packages, and updated Elasticsearch.

Machine Learning

Predicting Chemical Safety for Drug Discovery

In this work, I illustrated the advantages of using multi‐label models for compounds toxicity assessment even when toxicity data is partially available.